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Abstract Lysophosphatidic acid (LPA) is the smallest and
simplest of all the glycerophospholipids that activates a specific
GTP-binding protein coupled receptor to evoke multiple cellular
responses. In this paper, we have demonstrated that LPA
stimulates nuclear factor (NF)-UB-dependent gene induction in
a neuronal cell line, NG108-15 and that this is under redox
regulation by an endogenous molecule, thioredoxin. We also have
shown that redox-sensitive transactivation of epidermal growth
factor receptor by LPA confers NF-UB activation and small
GTPase proteins are involved in this pathway. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Lysophosphatidic acid (LPA; 1-acyl-2-lyso-sn-glycero-3-
phosphate) is a naturally occurring, water-soluble glycero-
phospholipid that exhibits striking hormone- and growth fac-
tor-like activities [1]. LPA is normally in serum and acts on
¢broblast, endothelial cells, and smooth muscle cells [2]. Cel-
lular responses to LPA include changes in cell shape, chemo-
taxis, proliferation, and di¡erentiation [1]. In neuronal cells, it
in£uences neurite extension and neurotransmitter release. It is
now well established that LPA induces cellular responses by
binding to a seven-transmembrane domain motif character-
istic of GTP-binding regulatory protein (G protein)-coupled
receptors (GPCRs) that is coupled to Gi, Gq, G12, and G13
subfamilies of heterotrimeric G protein [1,3]. It has been ob-
served that LPA, as well as other agonists of GPCRs, induces
tyrosine phosphorylation of several signalling proteins in di-
verse cell types. It was reported that LPA and some other
agonist of GPCRs, such as thrombin and bradykinin, trans-
activate the epidermal growth factor receptor (EGFR) [4].
Although a line of evidence clearly demonstrates the signi¢-
cance of this transactivation pathway for LPA-induced mito-
gen-activated protein kinase (MAPK) activation, there are
only a few reports on the other signalling pathways such as
nuclear factor (NF)-UB activation, which has been shown to
play a pivotal role in in£ammation and life and death of cells.
The binding of ligands to certain GPCRs leads to activation
of NF-UB. Ligands include serotonin, platelet-derived growth
factor, thrombin, and bradykinin [1]. In addition, LPA also
promotes activation of NF-UB in a ¢broblast cell line, Swiss
3T3 cells [5] and in primary endothelial cells [6]. Details of
mechanism from GPCR to NF-UB are largely unknown,
although the signalling pathway to the activation of NF-UB
from in£ammatory cytokines is one of the most extensively
studied [7]. As well as tumor necrosis factor, several extracel-
lular stimuli, including oxidative stress, activate NF-UB [8,9].
It has been reported that antioxidants, such as N-acetyl-L-
cysteine (NAC) and pyrolidine dithiocarbamate (PDTC), sup-
press the NF-UB activation in certain cells, indicating that the
activation of NF-UB is subject to redox regulation [7,9]. It has
been demonstrated that LPA stimulates reactive oxygen inter-
mediates (ROIs) production in HeLa cells and antioxidants
such as NAC or PDTC inhibit LPA-induced NF-UB activa-
tion [5]. However, NAC and PDTC are all synthesized com-
pounds and the details of mechanisms or target molecules are
not well described.
Thioredoxin (TRX) is a 12 kDa endogenous protein [10,11].
The TRX system including TRX reductase and NADPH, is
involved in the thiol-regulated intracellular redox system as
well as the glutathione system [11]. TRX has been shown to
regulate various cellular functions by modulating the redox
state of proteins and control the activities of various types
of transcription factors including NF-UB, AP-1 and CREB
[12^15]. TRX participates in redox reactions by reversible
oxidation of its active center dithiol to a disul¢de and has
peroxidase activity such as catalase [11,16]. Thus TRX is in-
volved in many thiol-dependent cellular processes including
proliferation and apoptosis, and gene expression and signal
transduction [13].
In this study, using a neuronal cell line, NG108-15, we
demonstrate that LPA transactivates EGFR, that this trans-
activation confers NF-UB activation by LPA and that an en-
dogenous thiol regulating molecule, TRX suppresses LPA-
elicited transactivation of EGFR and activation of NF-UB.
In addition, we show that certain alpha subunits of heterotri-
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meric G protein and Rho family small G proteins are playing
signi¢cant roles in this redox-sensitive pathway.
2. Materials and methods
2.1. Cell lines and reagents
Mouse neuroblastoma x rat glioma hybrid NG108-15 cells [17] are
from Dr. Haruhiro Higashida, Kanazawa University. NG108-15 cells
were maintained in DMEM supplemented with 5% FBS, 100 WM
hypoxanthine, 1 WM aminopterin, and 16 WM thymidine at 37‡C
under a humidi¢ed atmosphere of 5% CO2. LPA and NAC were
purchased from Sigma. Recombinant human EGF was from Boehr-
inger Mannheim GmbH. Monoclonal antibodies raised against EGF
receptor (E12020) and activated EGF receptor (E12120) were from
BD Transduction Laboratory. Tyrphostin AG1478, tyrphostin A25,
and pertussis toxin (PTX) were from Calbiochem.
2.2. Expression plasmids
Expression plasmids of wild-type human TRX and its redox-inac-
tive mutant, pcDNA3-TRX-wt and pcDNA3-TRX-dm, were de-
scribed elsewhere [14]. An expression plasmid of human IUBK32A/
36A mutant, pRcIUBK32A/36A [18], was from Dr. Nancy R. Rice,
NCI, Frederic. Constitutively activated G proteins, pcDNA3-Gq
Q209L, pcDNA3-G12 Q229L, and pcDNA3-G13 Q226L [19] were
kindly provided by Dr. Manabu Negishi, Kyoto University. Expres-
sion plasmids of small G proteins, Rac1 [20] and RhoA were gifts
from Dr. Kozo Kaibuchi, NAIST and Dr. Shu Narumiya, Kyoto
University respectively. pNF-UB-Luc and pSV-L-galactosidase were
from Stratagene and Promega, respectively. An expression vector of
GFP-fused EGF receptor, in which the GFP moiety is fused to the
carboxyl-terminus of EGFR, pEGFR-EGFP [21] was kindly provided
by Dr. Alexander Sorkins, University of Colorado, CO, USA.
pEGFP-N3 was obtained from Clontech.
2.3. Reporter gene assay
NG108-15 cells were plated in 24-well plates at a density of 5U104
cells per well. The Fugene 6 reagent (Roche) was used for the trans-
fection procedure. Total amount of DNA was adjusted equally with
pcDNA3. After treatment, the cells were harvested and the luciferase
activity was determined using an assay system (Promega) with a lu-
minometer, Lumat LB9507 (Berthold). The relative fold induction of
luciferase activity was calculated after normalization dividing the lu-
ciferase activity by L-galactosidase activity [14,15]. Each experiment
was done at least two times in triplicate and data shown are repre-
sentatives of them. The results are the means þ S.D. and presented as
relative luciferase activity over the baseline seen with the mock trans-
fectant.
2.4. Western blotting
After treatments, cells were lysed with a bu¡er (5 mM HEPES;
250 mM NaCl, 10% (v/v) glycerol, 0.5% Nonidet P-40, 100 WM
Va3VO4 supplemented by Complete protease inhibitor cocktail,
Roche). 50 Wg of lysates were separated on 7.5% SDS^PAGE gels.
Western blotting analysis was performed following a protocol de-
scribed previously [14].
2.5. Statistical analysis
Statistical signi¢cance between two groups was tested using the
unpaired Student’s t test. Di¡erences were considered statistically sig-
ni¢cant at a value of P6 0.05.
3. Results
3.1. Induction of NF-UB-dependent luciferase activity by LPA
is redox-sensitive
To examine e¡ect of LPA on NF-UB-dependent transcrip-
tional activity, we treated NG108-15 cells with LPA. As
shown in Fig. 1A, 20 WM of LPA signi¢cantly induced acti-
vation of NF-UB. Overexpression of mutant form of IUBK,
IUBK32A/36A inhibited the LPA-induced activation. Overex-
pression of wild-type TRX in a plasmid-dose responsive man-
ner or treatment with NAC inhibited the LPA-induced acti-
vation (Fig. 1B). A mutant-type TRX, which has no reducing
activity, did not suppress the activation. Interestingly, TRX
expression did not inhibit IKKK-induced NF-UB activation
(data not shown) in NG108-15 cell as well as in HEK293 cells
[22].
3.2. Involvement of EGFR in LPA-induced NF-UB activation
Because it is well known that LPA transactivates EGFR
and this transactivation plays a vital role in LPA-induced
MAPK activation process [4,23], we examined whether this
is true in the case of the NF-UB activation. Tyrphostin
AG1478, a rather selective EGFR-autophosphorylation tyro-
sine kinase activity inhibitor, or tyrphostin A25 treatment
suppressed the NF-UB activation (Fig. 2A). In consistency
Fig. 1. Induction of NF-UB-dependent luciferase activity by LPA is
TRX-sensitive. NG108-15 cells were transfected with 250 ng of
pNF-UB-Luc, 100 ng of pSV-L-galactosidase, and an indicated
amount of pRc-IUBK32A/36A, pcDNA3-TRX-wt or pcDNA3-TRX-
dm. At 12 h after transfection, cells were treated by LPA with or
without NAC pretreatment. After 6 h incubation, cells were har-
vested and underwent the luciferase assay following the protocol de-
scribed in Section 2. The results are the means þ S.D. and presented
as fold increase in luciferase activity over the baseline seen with the
mock transfectant without treatment (A) or as percent induction
over the mock transfectant with LPA treatment (B). This is a repre-
sentative of two independent experiments which were done in tripli-
cate. #P6 0.05.
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with this results, overexpression of EGF receptor signi¢cantly
enhanced LPA-induced NF-UB-dependent luciferase activity
compared to the pEGFP-N3 transfectants in NG108-15
(Fig. 2B). Treatment with 500 ng/ml of EGF stimulated
NF-UB activation less than with 20 WM of LPA. AG1478
treatment abolished the enhancement of NF-UB activation
by overexpression of EGFR in NG108-15 cells (data not
shown).
3.3. LPA-induced EGFR transactivation is under redox
regulation
Next we examined if LPA-induced EGFR activation is re-
dox-sensitive or not. NG108-15 cells were transfected with
pEGFR-EGFP and treated with LPA with or without exo-
genous TRX expression or NAC treatment. As shown in Fig.
3, LPA transactivated EGFR (lane 2) and this was suppressed
by wild-type TRX expression (lane 3) or NAC treatment (lane
4).
3.4. Activation of NF-UB by Gq, G12 or G13 is TRX-sensitive
The LPA receptor has been shown to be a seven-transmem-
brane domain motif characteristic of GPCRs that is coupled
to Gi, Gq, G12, or G13 subfamilies of heterotrimeric G pro-
tein [1]. LPA-induced NF-UB activation was suppressed by
Fig. 2. Involvement of EGFR activation in LPA-induced NF-UB ac-
tivation. NG108-15 cells were transfected with 250 ng of pNF-UB-
Luc and 100 ng of pSV-L-galactosidase with (B) or without (A)
250 ng of pEGFR-EGFP or pEGFP-N3. 12 h after transfection,
cells were treated with or without AG1478 (125 nM) or A25
(25 WM) for 1 h (A) and then treated with LPA. B: Cells were
treated with LPA (20 WM) or EGF (500 ng/ml). After 6 h treat-
ment, cells were harvested and underwent the luciferase assay. The
results are the means þ S.D. and presented as percent induction in
luciferase activity over the lane with LPA treatment (A) or as fold
increase over the baseline seen with the pEGFP-N3-transfectant
without treatment (B). This is a representative of two independent
experiments which were done in triplicate. #P6 0.05.
Fig. 3. Redox regulation of EGFR transactivation by LPA. NG108-
15 cells were transfected with pEGFR-EGFP with pcDNA3 or
pcDNA3-TRX-wt. After 12 h, cells were serum-starved for 12 h
and then stimulated for 15 min in the absence or presence of LAP
(40 WM). Cells were harvested and then subjected to Western blot-
ting analysis as described in Section 2.
Fig. 4. Activation of NF-UB by Gq, G12 or G13 is TRX-sensitive.
NG108-15 cells were transfected with 250 ng of pNF-UB-Luc and
100 ng of pSV-L-galactosidase. 6 h after transfection, cells were
treated with 50 ng/ml of PTX for 18 h and then stimulated with
LPA for 6 h (A). B: Cells were transfected with 250 ng of pNF-UB-
Luc, 100 ng of pSV-L-galactosidase, and 250 ng of pcDNA3-Gq
Q209L, pcDNA3-G12 Q229L, or pcDNA3-G13 Q226L with 250 ng
of pcDNA3 or pcDNA3-TRX-wt. Cells were incubated for 18 h.
The results are the means þ S.D. and presented as percent induction
over the lane without PTX treatment (A) or as fold increase over
the mock transfectant (B). This is a representative of two independ-
ent experiments which were done in triplicate. #P6 0.05.
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PTX treatment (Fig. 4A). This suggests that part of the NF-
UB-stimulating action of LPA is assigned to Gi. As next, we
tried constitutively activated form of Gq, G12, and G13. As
shown in Fig. 4B, overexpression of constitutively activated G
proteins by itself stimulated NF-UB activation. These activa-
tions were inhibited by overexpression of TRX or IUBK32A/
36A (data not shown).
3.5. Involvement of small GTPase in LPA-induced NF-UB
activation
Shahrestanifar et al. have reported that LPA stimulates
generation of ROI in HeLa cells and activation of NF-UB
[5]. This process is reported to be sensitive to DPI, a potent
inhibitor of £avonoid proteins, such as NADPH oxidase [24].
We investigated a possibility of involvement of a Rho family
small G protein, Rac1, which is one of the essential compo-
nents of NADPH oxidase system in even non-phagocytotic
cells [24]. As shown in Fig. 5A, overexpression of dominant
negative mutant of Rac1, Rac1-N17 dose-dependently sup-
pressed LPA-induced NF-UB activation. Moreover, overex-
pression of constitutively activated Rac1 mutant, Rac1-V12
by itself stimulated NF-UB activation in NG108-15 cells as
well as HEK293 cells and this was also TRX-sensitive (Fig.
5B). Expression of dominant negative form of Rho also sup-
pressed NF-UB activation as reported in HeLa cells [25].
4. Discussion
In this study, we have shown that LPA stimulates NF-UB-
dependent transcription in a redox-sensitive manner in
NG108-15 cells. The dose of LPA required for NF-UB acti-
vation was 10 WM in this study. This is higher than that
reported to inhibit adenylyl cyclase, activate ERKs, elevate
IP3 and Ca2, and stimulate formation of stress ¢ber and
focal adhesions but is similar to that needed for activation
of serum response factor and reinitiation of DNA synthesis
[3].
The molecular mechanism of LPA-induced NF-UB activa-
tion is largely unknown. Recently, in addition to TNF-recep-
tor-RIP-TRAF-NIK pathway, an alternative signalling path-
way has been described in certain cells in which Akt directly
phosphorylates IKK leading to the activation of NF-UB, in-
dependent of MAPK/ERK kinase kinase-1 (MEKK1) and
NF-UB inducible kinase (NIK) [26,27]. This pathway thus
allows growth factors such as PDGF to activate NF-UB
[28]. La¡argue et al. clearly demonstrated that LPA induces
phosphoinositide 3-kinase activation in a EGFR-dependent
manner [29]. We also have demonstrated that two di¡erent
PI3K inhibitors and EGFR inhibitors suppress NF-UB-depen-
dent gene expression. Another possible mechanism is the
MEKK1-dependent pathway. MEKK1 is another MAPK ki-
nase kinase which induces the degradation of IUBK and acti-
vates NF-UB-dependent reporter gene activation [30]. How-
ever, we have demonstrated that NF-UB activation by
overexpression of activated MEKK-1 or IKKK is TRX-sensi-
tive in neither HEK293 cells [22] nor NG108-15 cells (data not
shown). ROIs enhance the EGFR phosphorylation in ligand-
independent manners [31] and H2O2 treatment induced
EGFR phosphorylation in NG108-15 cells and A431 cells
(K.H., unpublished observation). This is consistent with our
results with NAC and TRX (Fig. 3). Although it is unclear
how ROI is involved in this process, a plausible mechanism is
the inactivation of protein tyrosine phosphatases (PTP) [32].
Because all PTPs have catalytic sites containing reactive cys-
teine residues, which form a thiol-phosphatase intermediate
during catalysis, oxidation of these residues leads to their in-
activation and overexpression of thiol-reducing TRX may re-
duce oxidized residues.
The LPA receptor is a GPCR that is coupled to Gi, Gq,
and G12/13 subfamilies of G proteins [1]. Our results using
PTX show that Gi is involved in this process, although we do
not have any de¢nitive evidence to which G proteins are
coupled to LPA receptor and play a major role in LPA-in-
duced NF-UB activation in NG108-15 cells. However, evi-
dence that the activation by LPA is not completely suppressed
by 50 ng/ml of PTX suggests that all of the action by LPA is
not assigned to Gi (Fig. 4A). Actually, Gq is expressed in
NG108-15 cells, and overexpression of constitutively active
Gq stimulates NF-UB activation (Fig. 4B). Overexpression
of constitutively active G12 or G13 stimulates NF-UB activa-
tion in NG108-15 cells (Fig. 4B), although involvement of this
G12/13 family G protein is to be investigated more as further
study. One of the downstream targets of both Gi and Gq is
the phosphoinositide-speci¢c phospholipase C-L, whose acti-
vation results in recruitment and activation of PKC [33].
Fig. 5. Involvement of small GTPase in LPA-induced NF-UB activa-
tion. NG108-15 cells were transfected with Rac1-DN or RhoA-DN
expression plasmids with 250 ng of pNF-UB-Luc and 100 ng of
pSV-L-galactosidase. At 12 h after transfection, cells were treated by
LPA. After 6 h incubation, cells underwent the luciferase assay (A).
B: Cells were transfected with 250 ng of Rac1-V12 or RhoA-wt ex-
pression plasmids with 250 ng of pNF-UB-Luc and 100 ng of pSV-
L-galactosidase with pcDNA3 or pcDNA3-TRX-wt. After 24 h, cells
were harvested and subjected to luciferase assay. The results are the
means þ S.D. and presented as percent induction over the mock
transfectant (A) or as fold increase over the mock transfectant (B).
This is a representative of two independent experiments which were
done in triplicate. %P6 0.05 compared with pEGFP-N3/TNF,
#P6 0.05 compared with pEGFR-EGFP/TNF.
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Shahrestanifar et al. demonstrated that in Swiss 3T3 cells, a
PKC inhibitor, Ro-31-8220, inhibits NF-UB activation by
LPA [5]. PKC activation has been shown to be under redox
regulation. H2O2 treatment stimulates PKC activation and
treatment with NAC or another antioxidant suppresses PKC
activation by extracellular stimuli [34]. Interestingly, TRX has
been identi¢ed as one of the PKC-binding proteins and re-
combinant TRX inhibits PKC phosphorylation activity in an
in vitro experiment [35]. Another common target for Gi, Gq,
G12, and G13, is the Rho family small GTPase protein. Rho
has been demonstrated to be a downstream molecule of LPA
[36]. Our results strongly suggest that in NG108-15 cells in
addition to Rho, another type of small G protein, Rac1, plays
an signi¢cant role in the LPA-stimulated NF-UB activation
pathway. Rac1 is an essential subunits of NADPH oxidase
system in even non-phagocytotic cells [24] and overexpression
of constitutively active mutant of Rac1 confers generation of
ROI in certain cells [24,37] and overexpression of dominant
negative mutant suppresses ROI generation by cytokines such
as TNF and IL-1 [38], and growth factors such as EGF [39]
and PDGF [40,41]. Because TRX has a peroxidase activity
like catalase by itself [16] and is an electron donor to peroxi-
dase such as peroxiredoxin (Prx) [42], TRX scavenges H2O2,
one of the second messengers in the intracellular signalling
pathway.
LPA regulates life and death of various types of cells. NF-
UB is also shown to play a critical role in regulating cell fate
[43]. Recently a chemokine, fractalkine, produced by glia cells
activates PI3K and NF-UB via the CX(3)CR1 receptor, which
is a GPCR and puts a survival signal into neurons [44]. It
seems very interesting to examine the involvement of EGFR
in this system.
In summary, we have demonstrated that an endogenous
redox-acting molecule, TRX, regulates LPA-induced NF-UB
activation at various levels of signalling pathways in NG108-
15 cells.
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